{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307935","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.760953+00:00","generated_at":"2026-06-21T02:22:36.332104+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Madrigal Phase 3 MAESTRO-NASH meets dual primary endpoints; NDA planned H1 2023","bullets":["NASH resolution endpoint met: 30% on 100mg vs 10% placebo (p<0.0001); fibrosis improvement: 26% vs 14% (p=0.0002).","LDL-C lowering at 24 weeks: -16% on 100mg vs -1% placebo (p<0.0001); both doses statistically significant.","Safety similar across arms: SAEs 11.8-12.7%; discontinuation low (2.8-7.7%); common AEs mild diarrhea and nausea.","Company plans to file NDA for accelerated approval (Subpart H) in first half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307935","json":"https://secwatch.observer/filing/0001193125-22-307935.json","markdown":"https://secwatch.observer/filing/0001193125-22-307935.md","text":"https://secwatch.observer/filing/0001193125-22-307935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312522307935/0001193125-22-307935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312522307935/d423141d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:22:36.332104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}